Table 1 Baseline characteristic and clinical outcome of patients with rheumatic disease complicated by PJP, stratified by time to TMP/SMX initiation
Variables | Total (n = 37) | TMP-SMX ≤ 7 days1 (n = 27) | TMP-SMX > 7 days2 (n = 10) | P-value |
|---|---|---|---|---|
Age (years), mean ± SD | 50.1 ± 13.4 | 52.3 ± 13.2 | 43.9 ± 12.5 | 0.105 |
Sex (male), n (%) | 9 (24.3) | 7 (25.9) | 2 (20.0) | 0.999 |
Underlying rheumatic diseases, n (%) | ||||
Systemic lupus erythematosus | 14 (37.8) | 9 (33.3) | 5 (50.0) | 0.454 |
Dermatomyositis | 11 (29.7) | 6 (22.2) | 5 (50.0) | 0.125 |
Others3 | 12 (32.4) | 12 (44.4) | 0 (00.0) | NA |
Comorbidity, n (%) | ||||
Hypertension | 7 (18.9) | 4 (14.8) | 3 (30.0) | 0.360 |
Diabetes mellitus | 4 (10.8) | 3 (11.1) | 1 (10.0) | 0.999 |
Heart failure | 6 (16.2) | 4 (14.8) | 2 (20.0) | 0.653 |
Chronic renal dysfunction | 10 (27) | 7 (25.9) | 3 (30.0) | 0.999 |
Interstitial Pneumonia | 17 (45.9) | 10 (37.0) | 7 (70.0) | 0.136 |
Laboratory data, n (%) or median (IQR) | ||||
LDH > 500 U/L | 21(56.8) | 13(48.1) | 8(80.0) | 0.137 |
Lymphocyte count (109/L) | 0.5 (0.3–1.0) | 0.5 (0.3–1.0) | 0.6 (0.2–0.8) | 0.709 |
Albumin (g/L) | 27.0 (23.4–30.4) | 27.0 (23.5–30.0) | 29.0 (23.1–30.2) | 0.662 |
CD4 + lymphocyte count (cells/µL) | 121.8 (52.0–227.0) | 89.9 (59.0–192.0) | 153.5 (60.8–243.5) | 0.783 |
PaO2/FiO2 | 190.0 (120.0–263.5) | 221.0 (145.0–270.0) | 125.0 (100.0–222.5) | 0.089 |
C reactive protein (mg/L) | 58.7 (22.4–110.1) | 75.99 (25.2–113.9) | 50.0 (15.0–70.5) | 0.183 |
CMV viremia, n (%) | 16 (43.2) | 13 (48.2) | 3 (30.0) | 0.461 |
Medication before admission | ||||
Cyclophosphamide use, n (%) | 9 (24.3) | 9 (33.3) | 0 (0.0) | NA |
≧ 2 immunosuppressive agents use, n (%) | 8 (21.6) | 7 (25.9) | 1 (10.0) | 0.404 |
Methylprednisolone equivalent glucocorticoids (mg/d), median (IQR) | 40.0 (28.8–54.0) | 40.0 (30.0–50.0) | 40.0 (21.5–52.5) | 0.857 |
In-hospital treatment | ||||
Methylprednisolone equivalent glucocorticoids (mg/d), median (IQR) | 47.3 (37.7–65.7) | 43.2 (36.5–57.1) | 72.2 (37.2–86.5) | 0.039 |
Caspofungin use, n (%) | 30 (81.1) | 20 (74.1) | 10 (100.0) | 0.155 |
Mechanical ventilation, n (%) | 17 (45.9) | 8 (29.6) | 9 (90.0) | 0.002 |
90-day PJP-related mortality, n (%) | 15 (40.5) | 7 (25.9) | 8 (80.0) | 0.006 |